Ignite Creation Date:
2025-12-26 @ 10:46 PM
Ignite Modification Date:
2026-02-01 @ 7:05 PM
Study NCT ID:
NCT00171912
Status:
COMPLETED
Last Update Posted:
2017-02-23
First Post:
2005-09-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Imatinib mesylate | View |
| None | tyrosine kinases | View |
| None | imatinib sensitivity | View |
| None | Diverse malignancies either associated with | View |
| None | or thought to be associated with | View |
| None | activated tyrosine kinase enzymes | View |
| None | including hypereosinophilic syndrome | View |
| None | systemic mastocytosis | View |
| None | chronic myelomonocytic leukaemia, | View |
| None | dermatofibrosarcoma protuberans and other diseases. | View |
| None | Not included: | View |
| None | patients with chronic myeloid leukemia, | View |
| None | some other types of leukemias (abl-mutated) | View |
| None | some types of gastrointestinal stromal tumours (c-KIT-positive), | View |
| None | some systemic mastocytosis (if c-KIT D816V mutation), | View |
| None | brain, | View |
| None | prostate, | View |
| None | breast or lung cancers. | View |